Cystoid macular edema (CME) also known as Irvine Gass Syndrome is a painless disorder affecting the central retina or macula. This condition is characterized by multiple cysts like areas of fluid in the macula causing retinal swelling or edema. CME is the retinal thickening of macula due to disruption of the normal blood-retinal barrier which leads to leakage from the perifoveal retinal capillaries causing accumulation of fluid within the intracellular spaces of the retina, mainly in the outer plexiform layer. CME is of two types: pseudophakic and nonpseudophakic cystoid macular edema. Pseudophakic cystoids macular edema is when the cause of occurrence is known while nonpseudophakic is the condition where no specific clinical findings have been observed. Symptoms of cystoids macular edema are blurred or decreased central vision.
Highlights
The global Cystoid Macular Edema market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The cause of CME is not completely known though it may be accompanied by various diseases such as uveitis, vein occlusion or diabetes. It is also known to occur commonly after cataract surgery. Various risk factors associated with cystoids macular edema are penetrating keratoplasty (corneal transplant), retinal surgery, chronic renal failure, retinal vein occlusion, retinitis pigmentosa, systemic medication and topical prostaglandin analogs for glaucoma..No significant racial or sex related predilection exists for this condition. However, cystoids macular edema can occur at any age based on the etiology, though advanced age is at higher risk.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cystoid Macular Edema, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cystoid Macular Edema.
The Cystoid Macular Edema market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cystoid Macular Edema market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cystoid Macular Edema companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
EMMES
Fovea Pharmaceuticals
Icon Bioscience
Merck
Sanwa Kagaku Kenkyusho
Novartis
Johns Hopkins University
Wake Forest University
Iladevi Cataract
IOL Research Center
Rabin Medical Center
Kyushu University
Wills Eye Institute
Segment by Type
Non Steroidal Anti-Inflammatory Drugs
Anti- Vascular Endothelial Growth Factor (VEGF) Agents
Carbonic Anhydrase Inhibitors
Steroids
Segment by Application
Hospitals
Ambulatory Surgical Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cystoid Macular Edema companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cystoid Macular Edema 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Non Steroidal Anti-Inflammatory Drugs
1.2.3 Anti- Vascular Endothelial Growth Factor (VEGF) Agents
1.2.4 Carbonic Anhydrase Inhibitors
1.2.5 Steroids
1.3 麻豆原创 by Application
1.3.1 Global Cystoid Macular Edema 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cystoid Macular Edema 麻豆原创 Perspective (2018-2029)
2.2 Cystoid Macular Edema Growth Trends by Region
2.2.1 Global Cystoid Macular Edema 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cystoid Macular Edema Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Cystoid Macular Edema Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Cystoid Macular Edema 麻豆原创 Dynamics
2.3.1 Cystoid Macular Edema Industry Trends
2.3.2 Cystoid Macular Edema 麻豆原创 Drivers
2.3.3 Cystoid Macular Edema 麻豆原创 Challenges
2.3.4 Cystoid Macular Edema 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cystoid Macular Edema Players by Revenue
3.1.1 Global Top Cystoid Macular Edema Players by Revenue (2018-2023)
3.1.2 Global Cystoid Macular Edema Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Cystoid Macular Edema 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cystoid Macular Edema Revenue
3.4 Global Cystoid Macular Edema 麻豆原创 Concentration Ratio
3.4.1 Global Cystoid Macular Edema 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cystoid Macular Edema Revenue in 2022
3.5 Cystoid Macular Edema Key Players Head office and Area Served
3.6 Key Players Cystoid Macular Edema Product Solution and Service
3.7 Date of Enter into Cystoid Macular Edema 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Cystoid Macular Edema Breakdown Data by Type
4.1 Global Cystoid Macular Edema Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Cystoid Macular Edema Forecasted 麻豆原创 Size by Type (2024-2029)
5 Cystoid Macular Edema Breakdown Data by Application
5.1 Global Cystoid Macular Edema Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Cystoid Macular Edema Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Cystoid Macular Edema 麻豆原创 Size (2018-2029)
6.2 North America Cystoid Macular Edema 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cystoid Macular Edema 麻豆原创 Size by Country (2018-2023)
6.4 North America Cystoid Macular Edema 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cystoid Macular Edema 麻豆原创 Size (2018-2029)
7.2 Europe Cystoid Macular Edema 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cystoid Macular Edema 麻豆原创 Size by Country (2018-2023)
7.4 Europe Cystoid Macular Edema 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cystoid Macular Edema 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Cystoid Macular Edema 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cystoid Macular Edema 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Cystoid Macular Edema 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cystoid Macular Edema 麻豆原创 Size (2018-2029)
9.2 Latin America Cystoid Macular Edema 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cystoid Macular Edema 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Cystoid Macular Edema 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cystoid Macular Edema 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Cystoid Macular Edema 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cystoid Macular Edema 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Cystoid Macular Edema 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 EMMES
11.1.1 EMMES Company Detail
11.1.2 EMMES Business Overview
11.1.3 EMMES Cystoid Macular Edema Introduction
11.1.4 EMMES Revenue in Cystoid Macular Edema Business (2018-2023)
11.1.5 EMMES Recent Development
11.2 Fovea Pharmaceuticals
11.2.1 Fovea Pharmaceuticals Company Detail
11.2.2 Fovea Pharmaceuticals Business Overview
11.2.3 Fovea Pharmaceuticals Cystoid Macular Edema Introduction
11.2.4 Fovea Pharmaceuticals Revenue in Cystoid Macular Edema Business (2018-2023)
11.2.5 Fovea Pharmaceuticals Recent Development
11.3 Icon Bioscience
11.3.1 Icon Bioscience Company Detail
11.3.2 Icon Bioscience Business Overview
11.3.3 Icon Bioscience Cystoid Macular Edema Introduction
11.3.4 Icon Bioscience Revenue in Cystoid Macular Edema Business (2018-2023)
11.3.5 Icon Bioscience Recent Development
11.4 Merck
11.4.1 Merck Company Detail
11.4.2 Merck Business Overview
11.4.3 Merck Cystoid Macular Edema Introduction
11.4.4 Merck Revenue in Cystoid Macular Edema Business (2018-2023)
11.4.5 Merck Recent Development
11.5 Sanwa Kagaku Kenkyusho
11.5.1 Sanwa Kagaku Kenkyusho Company Detail
11.5.2 Sanwa Kagaku Kenkyusho Business Overview
11.5.3 Sanwa Kagaku Kenkyusho Cystoid Macular Edema Introduction
11.5.4 Sanwa Kagaku Kenkyusho Revenue in Cystoid Macular Edema Business (2018-2023)
11.5.5 Sanwa Kagaku Kenkyusho Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Cystoid Macular Edema Introduction
11.6.4 Novartis Revenue in Cystoid Macular Edema Business (2018-2023)
11.6.5 Novartis Recent Development
11.7 Johns Hopkins University
11.7.1 Johns Hopkins University Company Detail
11.7.2 Johns Hopkins University Business Overview
11.7.3 Johns Hopkins University Cystoid Macular Edema Introduction
11.7.4 Johns Hopkins University Revenue in Cystoid Macular Edema Business (2018-2023)
11.7.5 Johns Hopkins University Recent Development
11.8 Wake Forest University
11.8.1 Wake Forest University Company Detail
11.8.2 Wake Forest University Business Overview
11.8.3 Wake Forest University Cystoid Macular Edema Introduction
11.8.4 Wake Forest University Revenue in Cystoid Macular Edema Business (2018-2023)
11.8.5 Wake Forest University Recent Development
11.9 Iladevi Cataract
11.9.1 Iladevi Cataract Company Detail
11.9.2 Iladevi Cataract Business Overview
11.9.3 Iladevi Cataract Cystoid Macular Edema Introduction
11.9.4 Iladevi Cataract Revenue in Cystoid Macular Edema Business (2018-2023)
11.9.5 Iladevi Cataract Recent Development
11.10 IOL Research Center
11.10.1 IOL Research Center Company Detail
11.10.2 IOL Research Center Business Overview
11.10.3 IOL Research Center Cystoid Macular Edema Introduction
11.10.4 IOL Research Center Revenue in Cystoid Macular Edema Business (2018-2023)
11.10.5 IOL Research Center Recent Development
11.11 Rabin Medical Center
11.11.1 Rabin Medical Center Company Detail
11.11.2 Rabin Medical Center Business Overview
11.11.3 Rabin Medical Center Cystoid Macular Edema Introduction
11.11.4 Rabin Medical Center Revenue in Cystoid Macular Edema Business (2018-2023)
11.11.5 Rabin Medical Center Recent Development
11.12 Kyushu University
11.12.1 Kyushu University Company Detail
11.12.2 Kyushu University Business Overview
11.12.3 Kyushu University Cystoid Macular Edema Introduction
11.12.4 Kyushu University Revenue in Cystoid Macular Edema Business (2018-2023)
11.12.5 Kyushu University Recent Development
11.13 Wills Eye Institute
11.13.1 Wills Eye Institute Company Detail
11.13.2 Wills Eye Institute Business Overview
11.13.3 Wills Eye Institute Cystoid Macular Edema Introduction
11.13.4 Wills Eye Institute Revenue in Cystoid Macular Edema Business (2018-2023)
11.13.5 Wills Eye Institute Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
EMMES
Fovea Pharmaceuticals
Icon Bioscience
Merck
Sanwa Kagaku Kenkyusho
Novartis
Johns Hopkins University
Wake Forest University
Iladevi Cataract
IOL Research Center
Rabin Medical Center
Kyushu University
Wills Eye Institute
听
听
*If Applicable.
